MODERATOR | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus

KEYNOTE SPEAKER | Peter Marks, M.D., Ph.D., Independent Pharmaceutical Consultant; Former Director of the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

This session explores the cutting edge of personalized medicine beyond traditional gene testing, highlighting the clinical integration of next-generation diagnostic technologies. Experts will discuss the promise and practical application of proteomics, metagenomics, circulating tumor DNA (ctDNA), and digital diagnostic tools in delivering more precise, timely, and individualized care.

MODERATOR | Yuri Fesko, M.D., Senior Vice President & Chief Medical Officer, Quest Diagnostics

PANELIST | Esther Abels, Founder & Chief Executive Officer, SolarisRTC

PANELIST | Lourdes Barrera, Executive Director, Global Medical Affairs Oncology, Precision Medicine, Merck

PANELIST | David Kurtz, M.D., Ph.D., Co-Founder, Chief Medical Officer, Head of Research, Foresight Diagnostics

PANELIST | Ofer Sharon, M.D., Chief Executive Officer, OncoHost

This session will present updated findings from the groundbreaking research study analyzing clinical practice gaps in the implementation of personalized medicine for advanced non–small cell lung cancer (aNSCLC). Building on a previously published seven-step clinical practice gap framework, which identified key barriers to optimal use of biomarker-directed therapies, this new analysis uses more recent data to assess progress over the past four years. Attendees will gain insights into evolving clinical practice trends and ongoing challenges in delivering precision oncology.

PRESENTER | Susanne Munksted, Chief Precision Medicine Officer, Diaceutics

Industry innovation in diagnostic technologies and targeted treatment strategies drives progress in personalized medicine. But the path to market is fraught with obstacles. Pioneering investors and executives reflect on how to deal with challenges and uncertainty in an increasingly variable development and market environment.

MODERATOR | Kristin Ciriello Pothier, Life Sciences Sector Leader, Global Deal Advisory & Strategy Leader, Healthcare & Life Sciences, KPMG LLP

PANELIST | Namandje Bumpus, Ph.D., Strategic Advisor, Healthcare Policies and Scientific Strategy, Avalere Health; Former Principal Deputy Commissioner, U.S. Food and Drug Administration

PANELIST | Andy Moye, Ph.D., Senior Vice President & General Manager of Data Products, Tempus

PANELIST | Michael J. Pellini, M.D., Managing Partner, Section 32

MODERATOR | TBC 

KEYNOTE SPEAKER | Helmy Eltoukhy, Ph.D., Co-Chief Executive Officer & Chairman of the Board, Guardant Health

KEYNOTE SPEAKER | AmirAli Talasaz, Ph.D., Co-Chief Executive Officer & Director, Guardant Health

By detecting molecular cancer signals in blood samples of seemingly healthy patients, a new generation of early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner, when cancer may be more effectively treated. What might this mean for the future of cancer care? Leading voices discuss.

MODERATOR | Omar Perez, Ph.D., U.S. Head of Medical Diagnostics, AstraZeneca

PANELIST | Tomasz Beer, M.D., Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

PANELIST | Ora K. Gordon, M.D., Executive Director of Cancer Services, St. John Cancer Institute & Disney Family Cancer Center, Providence Health

PANELIST | Eric Klein, M.D., Distinguished Scientist, GRAIL

PANELIST | Dawn Mattoon, Ph.D., Chief Executive Officer, Mercy BioAnaytics, Inc.

MODERATOR | TBC 

KEYNOTE SPEAKER | TBC 

Machine learning and artificial intelligence technologies can drive biomarker discovery and validation and more readily explore divergent effects of preventive and treatment interventions across extensive data sets. What might this mean for the future of personalized medicine and what is being done to realize that future?

MODERATOR | Douglas Clark, M.D., Chief Pathologist, Life Sciences & Diagnostics Markets Group, Agilent Technologies

PANELIST | Michael Montalto, Ph.D., Vice President, Precision Medicine Global Development, Amgen

PANELIST | TBC

PANELIST | TBC

PANELIST | TBC

PRESENTER | William S. Dalton, Ph.D., M.D., Founder & Senior Advisor, Aster Insights; Emeritus Senior Member, H. Lee Moffitt Cancer Center and Research Institute

AWARDEE | George Poste, D.V.M., Ph.D., Regents’ Professor and Del E. Webb Chair in Health Innovation; Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University

MODERATOR | Dan Roden, M.D., Professor of Medicine, Pharmacology, & Biomedical Informatics; Senior Vice President, Personalized Medicine, Vanderbilt University Medical Center

PANELIST | Doug Biehn, President & Chief Executive Officer, Octave Bioscience, Inc.

PANELIST | Edward Hickey, President & Chair, American Association of Kidney Patients (AAKP) Veterans Health Initiative, U.S.M.C.

PANELIST | Damon Hostin, Global Lead, Market Access, Illumina

PANELIST | Brad Perkins, M.D., Chief Medical Officer, Karius, Inc.

Engaging with the global community is now more vital than ever for advancing personalized medicine, especially when considering shared knowledge, coordinated policy development, and international clinical adoption strategies. With rapid innovations in advanced technologies—including cell-based and gene therapies—new models of care are emerging, such as regional clinical delivery hubs in Europe designed to streamline patient access and accelerate implementation. Speakers will discuss efforts to harmonize regulatory frameworks and other innovative approaches to ensure equitable, timely delivery of transformative therapies worldwide.

MODERATOR | David Morrow, Ph.D., Scientific Lead for Advanced Therapies, European Infrastructure for Translational Medicine (EATRIS)

PANELIST | Gabriele Allegri, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

PANELIST | Ayah Ziyada, M.Sc. Ph.D. Candidate, Precision Medicine Program Manager, Center for Clinical Precision Medicine and Genomics, Hamad Medical Corporation, Qatar

PANELIST | TBC